Graphy selected for Seoul IP Center's 2026 Global IP Star Company program to build 'technological moat

Graphy, a South Korean digital orthodontic solutions company specializing in shape memory alloy (SMA) based clear aligners, has been selected for the Seoul Intellectual Property Center's 2026 Global IP Star Company program. The three-year program provides Graphy with tailored support for overseas patent, trademark, and design strategy, IP management diagnostics, and brand and design enhancement. CEO Shim Woon-seop confirmed the company will use the support to accelerate global IP portfolio expansion around its core SMA and 3D printing technologies, aiming to create structural barriers to competitor entry. The selection follows Graphy's consecutive export awards: $3 million in 2023, $5 million in 2024, and $7 million in 2025, and its recent designation as a 'Strong Small Enterprise' for surpassing $10 million in annual exports.

This move fits the IP lock-in grind pattern (P3) that is increasingly critical in the medical-dental vertical, where regulatory and patent barriers can create durable competitive moats. Graphy's Shape Memory Aligner technology represents a material-science differentiation within the clear aligner market, which is dominated by Align Technology's thermoformed approach using vat photopolymerization (VPP) for mass production. By securing international patents on SMA-based aligners and their 3D printing production methods before the technology reaches broad clinical adoption, Graphy is attempting to pre-empt the kind of commoditization that has affected conventional clear aligner manufacturing. The company's export trajectory — tripling from $3M to over $10M in three years — suggests real clinical adoption, not just marketing momentum, giving its IP strategy commercial teeth.

From a practical standpoint, Graphy's success now depends on execution: converting IP filings into enforceable claims in North America and Europe, where Align's patent portfolio is deepest. The company must also demonstrate that its SMA aligners deliver clinically superior outcomes — not just different material properties — to justify the switching costs for orthodontists. For competitors watching this space, the key signal will be whether Graphy's granted patents cover the manufacturing process itself, or merely the device geometry, which would be easier to design around. This is a measured, defensible move by a company that has earned the right to think about moats, but the real test remains clinical adoption at scale.